Note: In the older articles MAT® treatment was referred to by other names including: chronic intermittent intravenous insulin therapy (CIIIT), metabolic activation therapy (MAT), pulsatile insulin, pulse insulin therapy (PIT), pulsatile intravenous insulin therapy (PIVIT) and hepatic activation. .
Review Articles
1. Chronic intermittent intravenous insulin therapy: a new frontier in diabetes therapy Aoki TT, Grecu EO, Arcangeli MA, Benbarka MM, Prescott P, Ahn JH. Diabetes Technol Ther. 2001 Spring;3(1):111-
2. Long-
3. Type I diabetes: The ‘sleeping liver’ hypothesis and its clinical implications. Aoki TT, Benbarka MM. Modern Medicine 1992 60:73-
4. Type I diabetes: An intensive approach to controlling blood glucose levels. Aoki TT, Benbarka MM. 1992 Modern Medicine 60:88-
Nephropathy
Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy. Dailey GE, Boden GH, Creech RH, Johnson DG, Gleason RE, Kennedy FP, Weinrauch LA, Weir M, D’Elia JA. Metabolism. 2000 Nov;49(11):1491-
Effect of intensive insulin therapy on progression of overt nephropathy in patients with type 1 diabetes mellitus. Aoki TT, Grecu EO, Gollapudi GM, Barber AR, Arcangeli MA, Benbarka MM, Prescott P, Meisenheimer R. Endocr Pract. 1999 Jul-
A pilot study to test the effect of pulsatile insulin infusion on cardiovascular mechanisms that might contribute to attenuation of renal compromise in type 1 diabetes mellitus patients with proteinuria. Weinrauch LA, Burger AJ, Aepfelbacher F, Lee AT, Gleason RE, D’Elia JA. Metabolism. 2007 Nov;56(11):1453-
Pulsatile intermittent intravenous insulin therapy for attenuation of retinopathy and nephropathy in type 1 diabetes mellitus. Weinrauch LA, Sun J, Gleason RE, Boden GH, Creech RH, Dailey G, Kennedy FP, Weir MR, D’Elia JA. Metabolism. 2010 Oct;59(10):1429-
Utilization of an abbreviated diabetes impact management scale to assess change in subjective disability during a trial of pulsatile insulin delivery demonstrates benefit.Weinrauch LA, Bayliss G, Gleason RE, Lee AT, D’Elia JA. Metabolism. 2009 Apr;58(4):488-
Hypertension
Effect of chronic intermittent intravenous insulin therapy on antihypertensive medication requirements in IDDM subjects with hypertension and nephropathy. Aoki TT, Grecu EO, Prendergast JJ, Arcangeli MA, Meisenheimer R. Diabetes Care. 1995 Sep;18(9):1260-
Effect of intensive insulin therapy on abnormal circadian blood pressure pattern in patients with type I diabetes mellitus Aoki TT, Grecu EO, Arcangeli MA, Meisenheimer R.Online J Curr Clin Trials. 1995 Dec 15;Doc No 199:
Hypotension
Chronic intermittent intravenous insulin therapy corrects orthostatic hypotension ofdiabetes Aoki TT, Grecu EO, Arcangeli MA.Am J Med. 1995 Dec;99(6):683-
Hypoglycemia
Long-
Cardiology
Reversal of severe nonischemic dilated cardiomyopathy by intensive intravenous insulin therapy in a patient with NIDDM. Aoki TT, Grecu EO, Arcangeli MA. J Investigative Med. 1996 Jan; 44(1): 126A
Obstetrics
The effect of chronic intermittent intravenous insulin therapy on pregnancy outcome in insulin dependent diabetes mellitus. Field N, Boe N, Gilbert W, Benbarka M, Aoki T. Journal Soc. Gynecol. Invest. 1997; 4(1, supplement): 196A.
Quality of Life
Measurement of health status in diabetic patients: diabetes impact measurement scales.Hammond GS, Aoki TT. Diabetes Care 1992; 15: 469-
Physiology /Biochemistry
IGF-
Role of muscle in CO2 production after oral glucose administration in man. Meistas MT, Vlachokosta FV, Gleason RE, Arcangeli M, Aoki TT. Diabetes. 1985 Oct;34(10):960-
Evidence for restoration of hepatic glucose processing in type I diabetes mellitus. Aoki TT, Vlachokosta FV, Foss MC, Meistas MT. J Clin Invest. 1983 Apr;71(4):837-
Restoration of glucose homeostasis in insulin-